Politics & Law

The idea is simple enough to fit on an index card: instead of manufacturer rebates flowing to pharmacy benefit managers...

A sixteen-year-old patient who has been taking puberty blockers for three years and gender-affirming hormones for one is, depending on...

The compounding pharmacy that produces bioidentical hormone preparations for a clinic in Arizona may dispense thousands of monthly subscriptions to...

A drug priced at $400 in the United States and $80 in Germany is a shorthand the policy debate has...

In 1992, when Congress created the 340B Drug Pricing Program as a quiet rider on a Veterans Affairs reauthorization, the...

On January 1, 2026, the maximum fair prices Medicare negotiated for ten of its costliest drugs will take effect, and...

The premise seemed elegant: require pharmaceutical manufacturers to disclose the data behind drug price increases, and the resulting transparency would...

Every quarter, pharmaceutical manufacturers who want their drugs covered by Medicaid submit a number to CMS that determines how much...

The word "negotiation" appears throughout the Inflation Reduction Act's drug pricing provisions, and it is doing considerable work. In ordinary...

The modern American drug market was built on opacity, and then—suddenly—it was asked to explain itself. The Trump administration’s push...

Telemedicine was once described as the future of healthcare; today it resembles something more complicated—an infrastructure whose permanence remains politically...

  Policy frameworks assume that therapies map cleanly to indications. Combination protocols blur that mapping. A GLP-1 agent prescribed for...